Skip to main content

Table 2 Ongoing clinical trials of novel agents in patients with PTCL

From: Therapeutic options in peripheral T cell lymphoma

Agent Targeting site Phase ID
Endostar Angiogenesis inhibitor II NCT02520219
Selinexor Selective inhibitor of nuclear export II NCT02314247
Tipifarnib Farnesyltransferase inhibitor II NCT02464228
Darinaparsin Organic arsenic compound I NCT01435863
Ixazomib Proteasome inhibitor II NCT02158975
Denileukin diftitox Interleukin fusion protein II NCT00050999
Forodesine PNP inhibitor I/II NCT01776411
Ruxolitinib JAK inhibitor II NCT01431209
Temsirolimus mTOR inhibitor I NCT01614197
Carfilzomib Proteasome inhibitor I NCT01336920
Panobinostat Pan-deacetylase inhibitor II NCT01261247
Clofarabine DNA synthesis inhibitor I/II NCT00644189
MK2006 AKT inhibitor II NCT01258998
Sorafenib Multikinase inhibitor II NCT00131937
Alefacept Immunosuppressive dimeric fusion protein I NCT00438802
Pembrolizumab PD-1 antibody II NCT02535247
  1. PNP purine nucleoside phosphorylase, JAK Janus kinases, mTOR mammalian target of rapamycin, PD-1 programmed death-1